Edward P. Acosta

11.6k total citations · 1 hit paper
214 papers, 8.1k citations indexed

About

Edward P. Acosta is a scholar working on Infectious Diseases, Virology and Pediatrics, Perinatology and Child Health. According to data from OpenAlex, Edward P. Acosta has authored 214 papers receiving a total of 8.1k indexed citations (citations by other indexed papers that have themselves been cited), including 162 papers in Infectious Diseases, 123 papers in Virology and 36 papers in Pediatrics, Perinatology and Child Health. Recurrent topics in Edward P. Acosta's work include HIV/AIDS drug development and treatment (147 papers), HIV Research and Treatment (122 papers) and HIV/AIDS Research and Interventions (86 papers). Edward P. Acosta is often cited by papers focused on HIV/AIDS drug development and treatment (147 papers), HIV Research and Treatment (122 papers) and HIV/AIDS Research and Interventions (86 papers). Edward P. Acosta collaborates with scholars based in United States, United Kingdom and Zambia. Edward P. Acosta's co-authors include Courtney V. Fletcher, Roy M. Gulick, Heather J. Ribaudo, David W. Haas, John G. Gerber, Jennifer R. King, David B. Clifford, Daniel R. Kuritzkes, G. Wilkinson and Linda M. Page and has published in prestigious journals such as New England Journal of Medicine, The Lancet and JAMA.

In The Last Decade

Edward P. Acosta

205 papers receiving 7.9k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Impact of lipid nanoparticle size on mRNA vaccine immunogenicity

2021 256 citations Edward P. Acosta et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Edward P. Acosta United States	49	5.7k	4.0k	1.6k	1.1k	965	214	8.1k
Courtney V. Fletcher United States	48	5.5k 1.0×	4.2k 1.0×	2.1k 1.4×	1.3k 1.2×	702 0.7×	230	8.4k
Saye Khoo United Kingdom	50	6.0k 1.0×	3.0k 0.7×	2.1k 1.3×	1.5k 1.4×	749 0.8×	331	9.0k
Stephen C. Piscitelli United States	52	4.4k 0.8×	2.1k 0.5×	2.1k 1.3×	564 0.5×	1.0k 1.1×	169	7.9k
Roy M. Gulick United States	50	8.3k 1.5×	6.7k 1.7×	1.9k 1.2×	1.6k 1.5×	883 0.9×	168	10.6k
Giovanni Di Perri Italy	43	3.8k 0.7×	1.6k 0.4×	2.2k 1.4×	825 0.8×	717 0.7×	418	7.7k
Angela D. M. Kashuba United States	56	6.7k 1.2×	4.9k 1.2×	2.9k 1.8×	839 0.8×	1.1k 1.2×	314	11.2k
Tomáš Cihlář United States	51	7.8k 1.4×	2.6k 0.6×	2.8k 1.7×	708 0.7×	2.2k 2.3×	143	11.3k
David M. Burger Netherlands	56	9.0k 1.6×	4.4k 1.1×	3.3k 2.1×	2.0k 1.8×	1.1k 1.1×	497	13.4k
Charles Flexner United States	51	5.7k 1.0×	5.3k 1.3×	2.4k 1.5×	921 0.9×	1.5k 1.6×	181	10.8k
Anton Pozniak United Kingdom	53	8.2k 1.4×	5.2k 1.3×	3.5k 2.2×	1.9k 1.7×	616 0.6×	294	10.7k

Countries citing papers authored by Edward P. Acosta

Since Specialization

Citations

This map shows the geographic impact of Edward P. Acosta's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Edward P. Acosta with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Edward P. Acosta more than expected).

Fields of papers citing papers by Edward P. Acosta

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Edward P. Acosta. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Edward P. Acosta. The network helps show where Edward P. Acosta may publish in the future.

Co-authorship network of co-authors of Edward P. Acosta

This figure shows the co-authorship network connecting the top 25 collaborators of Edward P. Acosta. A scholar is included among the top collaborators of Edward P. Acosta based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Edward P. Acosta. Edward P. Acosta is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Acosta, Edward P., et al.. (2025). Influenza Antiviral Pharmacokinetic-Pharmacodynamic Relationships in Pregnancy, Infancy, and Early Childhood. The Journal of Infectious Diseases. 232(Supplement_3). S286–S298. 2 indexed citations

Acosta, Edward P., Inmaculada Aban, Kevin J. Ryan, et al.. (2025). Ganciclovir Dosing in Premature Infants Receiving Treatment for Congenital Cytomegalovirus Infection: Results of a Prospective Pharmacokinetic Study. The Journal of Infectious Diseases.

Flexner, Charles, et al.. (2025). Long-acting Injectable Containing Lopinavir Eliminates Reliance on Ritonavir Pharmacokinetic Enhancement. The Journal of Infectious Diseases. 232(3). 607–611.

Devanand, D. P., Thomas Wısnıewskı, Qolamreza Razlighi, et al.. (2025). Valacyclovir Treatment of Early Symptomatic Alzheimer Disease. JAMA. 335(6). 511–511.

Vijaykumar, Kadambari, George M. Solomon, Jennifer S. Guimbellot, et al.. (2024). Ivacaftor for Chronic Obstructive Pulmonary Disease: Results from a Phase 2, Randomized Controlled Trial. American Journal of Respiratory and Critical Care Medicine. 211(5). 823–831. 1 indexed citations

Vijaykumar, Kadambari, George M. Solomon, Jennifer S. Guimbellot, et al.. (2024). Ivacaftor for Chronic Obstructive Pulmonary Disease- Results From a Phase 2, Randomized Controlled Trial. A3823–A3823. 1 indexed citations

Shaffer, Katherine A., Kevin J. Ryan, Edward P. Acosta, et al.. (2024). Evaluating the effects of ivacaftor exposure on Staphylococcus aureus small colony variant development and antibiotic tolerance. JAC-Antimicrobial Resistance. 6(6). dlae185–dlae185.

Devanand, Davangere P., Howard Andrews, William Charles Kreisl, et al.. (2020). Antiviral therapy: Valacyclovir Treatment of Alzheimer’s Disease (VALAD) Trial: protocol for a randomised, double-blind,placebo-controlled, treatment trial. BMJ Open. 10(2). e032112–e032112. 52 indexed citations

Bull, Marta E., Caroline M. Mitchell, Jaime Soria, et al.. (2018). Monotypic low-level HIV viremias during antiretroviral therapy are associated with disproportionate production of X4 virions and systemic immune activation. AIDS. 32(11). 1389–1401. 12 indexed citations

10.

Snook, K.A., Jacob Werner, Olga M. Ocón-Grove, et al.. (2018). Transdermal Delivery of Enfuvirtide in a Porcine Model Using a Low-Frequency, Low-Power Ultrasound Transducer Patch. Ultrasound in Medicine & Biology. 45(2). 513–525. 10 indexed citations

11.

Viani, Rolando M., Carmelita Alvero, Terry Fenton, et al.. (2015). Safety, Pharmacokinetics and Efficacy of Dolutegravir in Treatment-experienced HIV-1 Infected Adolescents. The Pediatric Infectious Disease Journal. 34(11). 1207–1213. 40 indexed citations

12.

Sandkovsky, Uriel, et al.. (2012). Measurement of plasma and intracellular concentrations of raltegravir in patients with HIV infection. AIDS. 26(17). 2257–2259. 9 indexed citations

13.

Long, Mary C., et al.. (2007). Development of a sensitive and specific liquid chromatography/mass spectrometry method for the determination of tenofovir in human plasma. Rapid Communications in Mass Spectrometry. 21(13). 2087–2094. 22 indexed citations

14.

Ribaudo, Heather J., David W. Haas, & Edward P. Acosta. (2006). Reply to Tong et al.. Clinical Infectious Diseases. 43(4). 542–544. 24 indexed citations

15.

Benjamin, H., Alison Lee, Edward P. Acosta, et al.. (2006). Field Performance of a Thin-Layer Chromatography Assay for Detection of Nevirapine in Umbilical Cord Blood. HIV Clinical Trials. 7(5). 263–269. 11 indexed citations

16.

Wu, Hulin, Yangxin Huang, Edward P. Acosta, et al.. (2005). Modeling Long-Term HIV Dynamics and Antiretroviral Response. JAIDS Journal of Acquired Immune Deficiency Syndromes. 39(3). 272–283. 66 indexed citations

17.

Goetzman, Eric S., Liqun Tian, Tim R. Nagy, et al.. (2003). HIV Protease Inhibitor Ritonavir Induces Lipoatrophy in Male Mice. AIDS Research and Human Retroviruses. 19(12). 1141–1150. 20 indexed citations

18.

Chen, Ray Y., Andrew O. Westfall, James L. Raper, et al.. (2002). Immunologic and Virologic Consequences of Temporary Antiretroviral Treatment Interruption in Clinical Practice. AIDS Research and Human Retroviruses. 18(13). 909–916. 18 indexed citations

19.

Acosta, Edward P. & John G. Gerber. (2002). Position Paper on Therapeutic Drug Monitoring of Antiretroviral Agents. AIDS Research and Human Retroviruses. 18(12). 825–834. 91 indexed citations

20.

Acosta, Edward P., Keith Henry, Linda M. Page, et al.. (1997). Pharmacokinetics and Safety of Concentration‐Controlled Oral Zidovudine Therapy. Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy. 17(3). 424–430. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact